

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 86605

Title: Case report: Response of Cholangiocarcinoma with Epigastric Metastasis to Lenvatinib plus Sintilimab

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03477763

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: China

Manuscript submission date: 2023-07-06

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-07-24 18:42

Reviewer performed review: 2023-07-30 13:01

Review time: 5 Days and 18 Hours

Scientific quality	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
Novelty of this manuscript	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Good <input type="radio"/> Grade C: Fair <input type="radio"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Good <input type="radio"/> Grade C: Fair <input type="radio"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

To Authors I congratulate the authors for Case report: Response of Cholangiocarcinoma with Epigastric Metastasis to Lenvatinib plus Sintilimab name's article. Best regards.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 86605

Title: Case report: Response of Cholangiocarcinoma with Epigastric Metastasis to Lenvatinib plus Sintilimab

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03740782

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: China

Manuscript submission date: 2023-07-06

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-08-14 02:47

Reviewer performed review: 2023-08-20 11:55

Review time: 6 Days and 9 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The case report and discussion of different responses of the intrahepatic and extrahepatic cholangiocarcinoma metastases to combining Lenvatinib with Sintilimab treatment are interesting. There are some issues: 1. How high is the levels of CA199 before and after Lenvatinib with Sintilimab? Is the CA199 level improved after the treatment? 2. Is the epigastric metastasis related to seeding of the surgical would? 3.

There is a typo in Page 7: “visplatin”. 4. In page, “Conversely, the immune microenvironment of extrahepatic tumors may be in an immune-activated state, making them more susceptible to attack by activated immune cells and the anti-angiogenesis effects of targeted immune drugs. This can ultimately induce tumor regression” is repeated. 5. The H&E pathological picture in Figure 3 (epigastric tumor biopsy) is in low quality. Please give a high power of view of the tumor glands and cancer cells in higher resolution. 6. Since there is a treatment effect in epigastric tumor, it would be better to show the PDL-1 staining (tumor cells or inflammatory cells) results and the amount of tumor infiltrating lymphocytes in the epigastric biopsy specimen. 7. Informed consent and/or IRB approval for case reporting (not surgical consent) are not included



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

in the submitted files.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 86605

Title: Case report: Response of Cholangiocarcinoma with Epigastric Metastasis to Lenvatinib plus Sintilimab

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03491790

Position: Editorial Board

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Thailand

Author's Country/Territory: China

Manuscript submission date: 2023-07-06

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-09-04 10:05

Reviewer performed review: 2023-09-04 12:09

Review time: 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The manuscript describes a case report of a stage IV cholangiocarcinoma (CCA) with liver and abdominal wall metastases that received palliative surgery and two cycles of combining Lenvatinib with Sintilimab. They found different responses of the intrahepatic and extrahepatic metastases to the same therapy. While the content seems interesting, the authors perhaps should elaborate on the differences in molecular targets of lenvatinib (a multiple receptor tyrosine kinase inhibitor) with Sintilimab (PD1) in extra- and intrahepatic CCA. This information may unravel the background behind this phenomenon. Also, there are some redundant sentences on Page 9. "Conversely, the immune microenvironment of extrahepatic tumors may be in an immune-activated state, making them more susceptible to attack by activated immune cells and the anti-angiogenesis effects of targeted immune drugs. This can ultimately lead to tumor regression. "